Charting a proven path in neuropsychiatry

Seaport Therapeutics (Seaport) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. All of the product candidates in its pipeline are based on its Glyph™ platform, which was initially advanced at PureTech and is now exclusively licensed to Seaport. Seaport applies Glyph to create novel product candidates for its pipeline, resulting in new intellectual property, including composition of matter patents.
Seaport’s pipeline includes its lead product candidate, GlyphAllo™ (SPT-300 or Glyph Allopregnanolone), a Glyphed oral prodrug of allopregnanolone, which is currently being evaluated in the Phase 2b BUOY-1 trial in patients with major depressive disorder (MDD) with or without anxious distress; GlyphAgo™ (SPT-320 or Glyph Agomelatine), a Glyphed oral prodrug of agomelatine, being advanced for the potential treatment of generalized anxiety disorder (GAD), which demonstrated positive topline data from its ongoing Phase 1 proof-of-concept trial in healthy adults; Glyph2BLSD™ (SPT-348 or Glyph 2-bromo-LSD), a Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, which is being advanced in preclinical studies for the treatment of depressive disorders, including treatment-resistant depression, post-traumatic stress disorder, and headache disorders. In addition to its three lead candidates, Seaport has robust discovery programs and multiple pipeline programs underway.
  • Patient Need
    • As of 2021, approximately 332 million people worldwide were affected by depression2 and approximately 21 million adults in the U.S. were affected by MDD.3 Quality of life can be severely impacted, and the societal economic burden of MDD in the U.S. alone was estimated at over $300 billion in 2019.4 Currently approved drugs for MDD often have significant limitations, including modest efficacy, slow onset of action, and unfavorable side effects, and approximately 4 in 10 people with MDD did not receive treatment as of 2021.3
    • Anxiety disorders are even more prevalent than MDD, and approximately 359 million people worldwide were affected as of 2021.5 Of these, approximately 100 million adults suffer from GAD, including more than seven million adults in the U.S.6 There have been no new therapies approved for GAD in almost two decades, and the medicines currently used for GAD have modest efficacy, slow onset, and/or unfavorable side effects.

2 World Health Organization, Depressive disorder (depression), fact sheet, updated August 29, 2025.
3 National Institute of Mental Health, Major Depression, statistics page, accessed April 14, 2026.
4 Greenberg PE, Fournier AA, Sisitsky T, et al., The economic burden of adults with major depressive disorder in the United States (2019–2020), Journal of Clinical Psychiatry, 2023.
5 World Health Organization, Anxiety disorders, fact sheet, updated September 8, 2025.
6 Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe. JAMA Psychiatry. 2017;74(5):465–475. doi:10.1001/jamapsychiatry.2017.0056

Seaport Therapeutics is advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. All the therapeutic candidates in the pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects.